No Data
BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Raises Target Price to $230
BofA Securities analyst Lyanne Harrison maintains $ResMed(RMD.US)$ with a buy rating, and adjusts the target price from $225 to $230.According to TipRanks data, the analyst has a success rate of 45.5%
Resmed Poised for Growth: Strong U.S. Device Sales and SaaS Segment to Drive Performance Despite Industry Challenges
Here's Why ResMed (RMD) Is a Strong Growth Stock
These Top ASX 200 Growth Shares Could Rise 20% to 45%
Fortunately for growth investors, there are a lot of quality options for them to choose from on the Australian share market.
ResMed(RMD.US) Officer Sells US$2.83 Million in Common Stock
$ResMed(RMD.US)$ Officer Farrell Michael J. sold 14,683 shares of common stock on Jul 8, 2024 at an average price of $192.9667 for a total value of $2.83 million.Source: Announcement What is
Insider Sale: CFO Brett Sandercock Sells Shares of ResMed Inc (RMD)
CyborgJack : tell us something we don't know! I can ask chatgpt for what you just told me lol.
Kevin TraversOP CyborgJack: do it then
Paul bin Anthony :
Kevin TraversOP Paul bin Anthony: WOAH HOLY CRUD
Rusty Shackleford 1 Kevin TraversOP: You didn't notice it says practice
View more comments...